Related Experiment Video

Updated: Mar 12, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Cabozantinib in genitourinary malignancies

Tian Zhang1, Se Eun Park1, Cierra Hong2

  • 1Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.

Future Oncology (London, England)
|November 16, 2016
PubMed

Insights

Cabozantinib effectively targets key cancer pathways, demonstrating significant improvements in progression-free and overall survival for advanced renal cell carcinoma patients in the METEOR study.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genitourinary Cancers

Background:

  • Cabozantinib targets multiple receptor tyrosine kinases (VEGFR1-3, MET, AXL, RET, FLT3, KIT) implicated in cancer growth.
  • These signaling pathways play a crucial role in the development and progression of genitourinary malignancies.

Purpose of the Study:

  • To review the clinical development and efficacy of cabozantinib in genitourinary cancers.
  • To highlight its activity in advanced renal cell carcinoma, prostate adenocarcinoma, and urothelial carcinoma.

Main Methods:

  • Review of clinical development data for cabozantinib.
  • Analysis of the METEOR study comparing cabozantinib to everolimus in advanced renal cell carcinoma.

Main Results:

  • Cabozantinib demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to everolimus in the METEOR study.
  • The drug exhibits notable activity in advanced renal cell carcinoma.

Conclusions:

  • Cabozantinib is an active agent in advanced renal cell carcinoma, with potential applications in other genitourinary malignancies.
  • Further investigation into its role in prostate adenocarcinoma and urothelial carcinoma is warranted.
Keywords:
cabozantinibgenitourinary malignanciesrenal cell carcinoma

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
710
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K